Berlex To Submit Angeliq NDA Response In March, Add Cardioprotective Data
Executive Summary
Schering AG's Berlex subsidiary expects to complete its response to FDA on its NDA for the hormone replacement therapy Angeliq in March
You may also be interested in...
Schering AG Makes Oncology A Primary Focus; Dermatology No Longer “Core”
Schering AG is establishing a new global oncology business unit that will be headquartered in the U.S
Schering AG Makes Oncology A Primary Focus; Dermatology No Longer “Core”
Schering AG is establishing a new global oncology business unit that will be headquartered in the U.S
Seasonale DTC Ads Will Help “Mainstream” Extended-Regimen OCs, Barr Says
Barr is hoping to "mainstream" the concept of extended-regimen oral contraceptives with a direct-to-consumer campaign for Seasonale